glp 1 agonists in development Evolution of GLP‐1 Receptor for Diabetes Treatment GLP-1 Receptor Agonist Services for

Those with obesity might have other serious chronic health conditions, including diabetes and high blood pressure, which are leading risk factors for heart disease and stroke

The development of dual GIPRGLP1R coagonists that bind to either one or the other receptor (sequence-mixed dual agonists) has emerged as an innovative therapeutic strategy for obesity and type 2 diabetes

However, there was no significant difference in adverse CVEs or all-cause mortality when compared with those taking SGLT2 inhibitors

The GLP-1 Receptor Agonist market size is expected to reach $18.32 billion in 2030 at a CAGR of 5.4%, driven by rising prevalence of diabetes.